Aeolus Pharmaceuticals (AOLS) Stock Price, News & Analysis

Company Overview

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AOLS Stock Analysis - Frequently Asked Questions

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) issued its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter.

How do I buy shares of Aeolus Pharmaceuticals?

Shares of AOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aeolus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeolus Pharmaceuticals investors own include Myriad Genetics (MYGN), Nutra Pharma (NPHC), Titan Pharmaceuticals (TTNP), ADOMANI (ADOM), Agritek (AGTK) and

Company Calendar

• Last Earnings: 8/14/2017
• Today: 5/07/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AOLS
• CIK: 1261734
• Web: www.aeoluspharma.com
• Phone: (949) 481-9825
• Fax: 949-481-9829
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.00